PTC Therapeutics (PTCT) Stock Forecast & Price Target

Compare

386 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PTCT Analyst Ratings

Moderate Buy

11 Buy

5 Hold

0 Sell

Based on 16 analysts giving stock ratings to

PTC

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PTCT Stock 12 Month Forecast

Average Price Target

$67.93

▲(32.91% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $67.93 with a high forecast of $120.00 and a low forecast of $46.00. The average price target represents a 32.91% change from the last price of $51.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","121":"$121","52.75":"$52.8","75.5":"$75.5","98.25":"$98.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,52.75,75.5,98.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.59,54.08307692307692,59.57615384615385,65.06923076923077,70.5623076923077,76.05538461538461,81.54846153846154,87.04153846153847,92.53461538461539,98.0276923076923,103.52076923076923,109.01384615384615,114.50692307692307,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.59,50.07769230769231,51.565384615384616,53.05307692307693,54.540769230769236,56.02846153846154,57.51615384615385,59.003846153846155,60.49153846153847,61.979230769230774,63.46692307692308,64.9546153846154,66.4423076923077,{"y":67.93,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.59,48.39076923076924,48.191538461538464,47.9923076923077,47.793076923076924,47.59384615384616,47.394615384615385,47.19538461538462,46.996153846153845,46.79692307692308,46.597692307692306,46.39846153846154,46.199230769230766,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.17,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$67.93

Lowest Price Target$46.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$55

Buy

7.61%

Upside

Reiterated

07/30/25

PTC Therapeutics has a robust overall stock score driven by a strong financial turnaround and promising earnings call insights. The company's attractive valuation and strategic product launches offer growth potential. However, technical indicators and balance sheet concerns warrant caution.

Eliana MerleUBS

UBS

$71→$80

Buy

56.53%

Upside

Reiterated

07/30/25

PTC Therapeutics price target raised to $80 from $71 at UBSPTC Therapeutics price target raised to $80 from $71 at UBS

Dex Genotek TR | OpenAI - 4o

TR | OpenAI - 4o

$49→$55

Buy

7.61%

Upside

Reiterated

07/30/25

Joon LeeTruist Financial

Truist Financial

$80→$86

Buy

68.26%

Upside

Reiterated

07/29/25

Truist Financial Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$112→$120

Buy

134.79%

Upside

Reiterated

07/29/25

PTC Therapeutics (PTCT) Gets a Buy from Cantor FitzgeraldCantor Fitzgerald analyst Kristen Kluska raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $120.00 (from $112.00) while maintaining an Overweight rating.

Gena WangBarclays

Barclays

$42→$46

Hold

-10.00%

Downside

Reiterated

07/29/25

Barclays Keeps Their Hold Rating on PTC Therapeutics (PTCT)

Tiago FauthWells Fargo

Wells Fargo

$74→$78

Buy

52.61%

Upside

Reiterated

07/29/25

Positive Outlook for PTC Therapeutics' Sephience: Strong Market Potential and Revenue Prospects

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

07/29/25

PTC Therapeutics Receives Buy Rating Following FDA Approval of Sephience and Strategic Market Positioning

Joseph ThomeTD Cowen

TD Cowen

$52

Hold

1.74%

Upside

Reiterated

07/29/25

TD Cowen Remains a Hold on PTC Therapeutics (PTCT)

Judah FrommerMorgan Stanley

Morgan Stanley

$70

Buy

36.96%

Upside

Reiterated

07/29/25

PTC Therapeutics: Buy Rating Driven by Sephience Approval and Market Strategy

Louise ChenScotiabank

Scotiabank

$55

Hold

7.61%

Upside

Reiterated

07/29/25

Scotiabank Remains a Hold on PTC Therapeutics (PTCT)

Geoff MeachamCiti

Citi

$40→$50

Hold

-2.17%

Downside

Reiterated

07/28/25

Citi Sticks to Its Hold Rating for PTC Therapeutics (PTCT)

Tazeen AhmadBank of America Securities

Bank of America Securities

$68→$84

Buy

64.35%

Upside

Reiterated

07/28/25

Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Following Sephience Approval and Strategic Launch

Joseph SchwartzLeerink Partners

Leerink Partners

$48→$50

Hold

-2.17%

Downside

Reiterated

07/25/25

Cautious Outlook on PTC Therapeutics: Sepiapterin's Limited Potential to Offset Declining DMD Revenues

Brian AbrahamsRBC Capital

RBC Capital

$58→$60

Buy

17.39%

Upside

Reiterated

07/07/25

PTC Therapeutics (PTCT) Gets a Buy from RBC Capital

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$55

Buy

7.61%

Upside

Reiterated

07/30/25

Eliana MerleUBS

UBS

$71→$80

Buy

56.53%

Upside

Reiterated

07/30/25

PTC Therapeutics price target raised to $80 from $71 at UBSPTC Therapeutics price target raised to $80 from $71 at UBS

Dex Genotek TR | OpenAI - 4o

TR | OpenAI - 4o

$49→$55

Buy

7.61%

Upside

Reiterated

07/30/25

Joon LeeTruist Financial

Truist Financial

$80→$86

Buy

68.26%

Upside

Reiterated

07/29/25

Truist Financial Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$112→$120

Buy

134.79%

Upside

Reiterated

07/29/25

Gena WangBarclays

Barclays

$42→$46

Hold

-10.00%

Downside

Reiterated

07/29/25

Barclays Keeps Their Hold Rating on PTC Therapeutics (PTCT)

Tiago FauthWells Fargo

Wells Fargo

$74→$78

Buy

52.61%

Upside

Reiterated

07/29/25

Positive Outlook for PTC Therapeutics' Sephience: Strong Market Potential and Revenue Prospects

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

07/29/25

PTC Therapeutics Receives Buy Rating Following FDA Approval of Sephience and Strategic Market Positioning

Joseph ThomeTD Cowen

TD Cowen

$52

Hold

1.74%

Upside

Reiterated

07/29/25

TD Cowen Remains a Hold on PTC Therapeutics (PTCT)

Judah FrommerMorgan Stanley

Morgan Stanley

$70

Buy

36.96%

Upside

Reiterated

07/29/25

PTC Therapeutics: Buy Rating Driven by Sephience Approval and Market Strategy

Louise ChenScotiabank

Scotiabank

$55

Hold

7.61%

Upside

Reiterated

07/29/25

Scotiabank Remains a Hold on PTC Therapeutics (PTCT)

Geoff MeachamCiti

Citi

$40→$50

Hold

-2.17%

Downside

Reiterated

07/28/25

Citi Sticks to Its Hold Rating for PTC Therapeutics (PTCT)

Tazeen AhmadBank of America Securities

Bank of America Securities

$68→$84

Buy

64.35%

Upside

Reiterated

07/28/25

Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Following Sephience Approval and Strategic Launch

Joseph SchwartzLeerink Partners

Leerink Partners

$48→$50

Hold

-2.17%

Downside

Reiterated

07/25/25

Cautious Outlook on PTC Therapeutics: Sepiapterin's Limited Potential to Offset Declining DMD Revenues

Brian AbrahamsRBC Capital

RBC Capital

$58→$60

Buy

17.39%

Upside

Reiterated

07/07/25

PTC Therapeutics (PTCT) Gets a Buy from RBC Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PTC Therapeutics

1 Month

xxx

Success Rate

13/17 ratings generated profit

Average Return

+7.21%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.47% of your transactions generating a profit, with an average return of +7.21% per trade.

3 Months

xxx

Success Rate

11/14 ratings generated profit

Average Return

+10.46%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +10.46% per trade.

1 Year

Joel BeattyRobert W. Baird

Success Rate

16/17 ratings generated profit

Average Return

+41.95%

reiterated a buy rating 3 months ago

Copying Joel Beatty's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +41.95% per trade.

2 Years

xxx

Success Rate

16/17 ratings generated profit

Average Return

+60.47%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +60.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTCT Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PTCT has received 31 Buy Ratings, 28 Hold Ratings, and 0 Sell Ratings. PTCT average Analyst price target in the past 3 months is 67.93.

Each month's total comprises the sum of three months' worth of ratings.

PTCT Financial Forecast

PTCT Earnings Forecast

Next quarter’s earnings estimate for PTCT is -$1.04 with a range of -$1.77 to -$0.37. The previous quarter’s EPS was $10.04. PTCT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year PTCT has Outperformed its overall industry.

PTCT Sales Forecast

Next quarter’s sales forecast for PTCT is $170.95M with a range of $146.70M to $198.50M. The previous quarter’s sales results were $1.18B. PTCT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year PTCT has Outperformed its overall industry.

PTCT Stock Forecast FAQ

What is PTCT’s average 12-month price target, according to analysts?

Based on analyst ratings, PTC Therapeutics’s 12-month average price target is 67.93.

What is PTCT’s upside potential, based on the analysts’ average price target?

PTC Therapeutics has 32.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTCT a Buy, Sell or Hold?

PTC Therapeutics has a consensus rating of Moderate Buy which is based on 11 buy ratings, 5 hold ratings and 0 sell ratings.

What is PTC Therapeutics’s price target?

The average price target for PTC Therapeutics is 67.93. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $46.00. The average price target represents 32.91% Increase from the current price of $51.11.

What do analysts say about PTC Therapeutics?

PTC Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of PTCT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

PTC Therapeutics (PTCT) Stock Forecast & Price Target

PTCT Analyst Ratings

PTCT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering PTC Therapeutics

PTCT Analyst Recommendation Trends

PTCT Financial Forecast

PTCT Earnings Forecast

PTCT Sales Forecast

PTCT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts